Puma Biotechnology, Inc.
PBYI
$8.83
$0.121.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.75% | -2.59% | 27.72% | -32.36% | 11.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.75% | -2.59% | 27.72% | -32.36% | 11.37% |
| Cost of Revenue | 1.41% | -1.25% | 66.13% | -58.16% | 15.42% |
| Gross Profit | 9.70% | -2.99% | 15.88% | -17.77% | 10.19% |
| SG&A Expenses | -2.77% | 4.65% | 10.57% | -0.01% | -27.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.81% | 15.75% | 27.64% | -23.20% | -7.03% |
| Operating Income | 14.30% | -196.08% | 27.99% | -56.64% | 404.54% |
| Income Before Tax | 33.74% | -204.90% | 39.79% | -55.15% | 248.52% |
| Income Tax Expenses | -81.94% | 11.26% | 151.92% | 37.11% | -17.99% |
| Earnings from Continuing Operations | 39.86% | -226.19% | -30.39% | -56.47% | 229.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.86% | -226.19% | -30.39% | -56.47% | 229.28% |
| EBIT | 14.30% | -196.08% | 27.99% | -56.64% | 404.54% |
| EBITDA | 7.47% | -118.35% | 28.08% | -50.74% | 1,189.30% |
| EPS Basic | 36.50% | -223.00% | -32.12% | -57.62% | 225.59% |
| Normalized Basic EPS | 30.58% | -202.18% | 36.33% | -56.32% | 244.32% |
| EPS Diluted | 35.82% | -223.00% | -34.44% | -58.54% | 225.59% |
| Normalized Diluted EPS | 27.60% | -202.93% | 34.04% | -56.70% | 243.02% |
| Average Basic Shares Outstanding | 2.49% | 2.52% | 2.53% | 2.72% | 2.92% |
| Average Diluted Shares Outstanding | 4.89% | 1.88% | 4.28% | 3.57% | 3.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |